Quick Facts

• Condition Treated: Chronic, persistent pain
• Therapeutic Focus: Management of moderate to severe discomfort
• Key Action: Symptom relief and functional improvement

---

Therapeutic Overview of Damara

Damara is a prescription medication utilized in a therapeutic domain focused on pain management. The main use of Damara is to provide relief for chronic, persistent pain that may not be adequately controlled by non-opioid analgesics. It is an indicated therapy for patients experiencing moderate to severe discomfort over extended periods.

Benefits and Patient-Reported Outcomes

Potential benefits associated with Damara treatment center on improved quality of life through effective symptom relief. By reducing the intensity of discomfort, the medication helps patients achieve functional improvement, allowing for greater participation in daily activities. This patient-focused intervention is part of a broader care plan aimed at stabilizing the patient's condition.

Eligibility Map: Who Can and Cannot Use Damara

Eligibility Scope	Official Regulatory Status
Populations Allowed	Women of childbearing age who require oral contraception, including use during lactation/breastfeeding.
Contraindicated Groups	Use is absolutely prohibited in the presence of confirmed or suspected pregnancy, severe liver disease (including tumors), undiagnosed vaginal bleeding, and known or suspected sex-hormone-sensitive malignancies (like breast cancer).
Vascular/Metabolic Restriction	Contraindicated for women with current or history of venous thromboembolism (VTE). Patients with diabetes mellitus require careful observation during the initial months of use.
Age Limitations	Adolescent use is permitted following menarche. The safety and efficacy are not established in girls before their first menstrual period (pre-menarche). The medicine is not indicated for use in post-menopausal women.

---

Connection to the overall eligibility profile:

Official regulatory documents define who can and cannot use this medicine by setting strict boundaries based on physiological state, age limitations, and absolute health contraindications. This ensures the medicine is restricted to the specific population of women of childbearing age whose clinical profile aligns with the documented parameters.

The regulatory interaction profile for Damara (Desogestrel) is defined by pharmacokinetic and pharmacodynamic constraints. Co-administration with certain medicinal products and non-medicinal substances can significantly alter the exposure of the active hormone, etonogestrel.

Interaction Type	Examples of Interacting Substances	Regulatory Outcome Description
Exposure Decrease	Rifampin, Carbamazepine, Phenytoin, St. John's wort	These CYP3A4 inducers accelerate hormone metabolism, resulting in reduced plasma concentrations of etonogestrel.
Exposure Increase	Itraconazole, Ketoconazole, Grapefruit Juice	These CYP3A4 inhibitors may increase the systemic exposure of the active hormone.
Contraindicated	Ombitasvir/Paritaprevir/Ritonavir/Dasabuvir	Combination is formally prohibited in regulatory labeling due to the documented risk of elevated liver enzymes.

---

Timing and Other Restrictions

Specific administrative separation is required to mitigate interaction risk. Colesevelam, a bile acid sequestrant, must be administered at least 4 hours before or after Damara to prevent reduced absorption caused by physical binding. A mandatory 5-day separation is necessary before starting Damara after taking the emergency contraceptive Ulipristal acetate. Additionally, the interaction profile notes that steroid hormones may be poorly metabolized in individuals with impaired liver function, a condition that can affect the drug's disposition and resulting interaction potential. This information governs the strict regulatory structure for co-administration.

Modulates Redox Signaling Pathways

This mechanistic domain involves Damara's interaction with the Keap1-Nrf2 complex. The drug's active metabolite alters the balance of cellular redox signaling, leading to the upregulation of protective antioxidant response elements (AREs) through transcriptional modulation.

---

Regulates Inflammatory Cascades

Damara affects key intracellular signaling pathways, such as the NF-κB pathway. By suppressing or inhibiting these specific signaling sequences, the drug directly alters the production and activity of inflammatory mediators, resulting in reduced mediator concentration.

---

Influences Cell-Cycle and Transcriptional Regulation

The mechanism engages intracellular processes that regulate cell-mediated activity, including effects on transcription factors and cell proliferation factors. This interaction modifies early molecular steps within pathways, leading to the regulation of molecular factors involved in cell-cycle control by adjusting distinct signaling patterns.

The usage of Damara is defined by a strict, continuous oral regimen for contraception. The administration route is oral, utilizing the single, fixed dose of the 75 microgram Desogestrel tablet. The dosing regimen requires taking one tablet daily, which is maintained continuously for 28 consecutive days, without any tablet-free interval between packs.

This continuous pattern requires the tablet to be administered once daily at approximately the same time every day, thereby establishing a precise 24-hour interval between doses. Adherence to this strict schedule is crucial. Protocol for managing deviations from this timing is clearly defined. If a tablet is taken less than 12 hours late (i.e., within a 36-hour total window), the missed tablet must be taken immediately. However, if the delay is more than 12 hours, the missed tablet must be taken, and an additional barrier method of contraception is required for the subsequent 7 days.

There are specific instructions for specialized use scenarios, such as immediately following a first-trimester abortion, and procedures for handling absorption issues; for instance, if vomiting occurs within 3 to 4 hours of administration, the missed-tablet rules apply. These parameters establish the fundamental pattern of use as continuous daily administration for as long as contraception is desired.

Research Evidence: Overview of Studies for Damara (Desogestrel)

Evidence Base for Pregnancy Prevention (Contraception)

Research exploring Damara's function centers on the investigation of contraceptive activity. Researchers have conducted numerous randomized controlled trials (RCTs) and systematic reviews to study the characteristics of its use, often comparing it against other older progestin-only pills (POPs). The key outcome measured in these trials is the Pearl Index, a calculation used in studies to monitor the occurrence of pregnancies during a defined period of use.

Research has explored patterns related to Desogestrel's use and its effect on biological markers. Research examined measured outcomes related to ovulation inhibition, assessed through specific physiological markers. Studies monitored outcomes related to ovulation suppression and compared the findings to some conventional POPs. However, evidence remains limited regarding direct trials comparing Desogestrel to combined oral contraceptives (COCs).

Research on Endometriosis-Related Pain

Research has also explored Damara's use in clinical situations involving outcomes related to physical discomfort for women with endometriosis. Researchers conducted trials comparing Desogestrel with placebo or to other hormonal therapies, primarily in patients receiving treatment after conservative surgery. The main study outcomes examined were patient-reported measures of pain intensity, such as the Visual Analogue Scale (VAS), to track the evolution of overall pelvic pain and dysmenorrhea.

Findings described patterns observed in the studies where trials documented the evolution of patient-reported pain scores during the study period. Systematic reviews comparing Desogestrel to other hormonal treatments indicate that the outcomes were often similar, and there is generally insufficient evidence to conclude that one hormonal treatment provides a better result than another for long-term symptom management.

Evidence in Specific Populations and Subgroups

Research has specifically explored the use of Desogestrel in postpartum women who are breastfeeding. Researchers monitored infant growth and potential effects on breast milk production in these studies. Multiple studies reported that use was associated with monitoring outcomes related to these parameters.

Common questions about Damara (FAQ)

---

Q: If I miss a pill, what is the exact time window I have before my protection is compromised, and what should I do?

Official product information provides specific instructions based on the time delay. If the tablet is taken less than 12 hours late, the missed tablet should be taken immediately, and the contraceptive protection is generally expected to be maintained. If the delay is more than 12 hours, the missed pill must be taken, and an additional non-hormonal barrier method is required for the following seven days due to the potential for lowered contraceptive reliability.

---

Q: What are the specific signs that my liver function is impaired, which would prevent me from taking Damara?

Regulatory warnings indicate that Damara is contraindicated in people with severe liver disease. Patient information indicates that signs such as jaundice (yellowing of the skin or eyes) or unexplained, severe stomach ache should prompt immediate consultation with a healthcare professional, as these may be possible indicators of liver problems.

---

Q: Does Damara interact with grapefruit juice, and if so, how?

Official drug labeling notes that Grapefruit Juice is considered a strong inhibitor of an enzyme called CYP3A4. This interaction may result in increased plasma concentrations (systemic exposure) of the active hormone, etonogestrel, which may affect the drug's profile.

---

Q: What do I do with the expired or unused tablets?

Regulatory documents state that expired or unused tablets must be disposed of correctly to protect the environment. The tablets must not be disposed of via wastewater or standard household waste. Disposal should be carried out according to local pharmaceutical requirements or by returning the product to a pharmacy or a designated drug take-back point.

---

Q: If I forget to take my pill on time, what is the maximum window I have before I should use backup contraception?

According to the official instructions, backup contraception is required if the tablet is taken more than 12 hours late. If the delay is less than 12 hours, a backup method is not required.

Official Storage Requirements

Damara (Desogestrel) tablets must be stored at a temperature that does not exceed 30 C. The official label specifies that the product must not be refrigerated or frozen. To maintain stability, the tablets require protection from light and moisture, which is achieved by keeping them in the original blister package and the outer carton. If the product is supplied in individual sachets, the contents must be used within one month after the sachet is first opened.

Disposal and Safety

For safety, Damara must be kept out of the sight and reach of children. Disposal of any unused or expired tablets must be conducted according to local pharmaceutical regulations. The medication should not be disposed of via wastewater or standard household waste.